What is semaglutide?
Semaglutide is a synthetic analogue of human glucagon-like peptide-1 (GLP-1), a hormone your gut naturally produces after eating. It's been engineered with a key modification: a fatty acid chain that binds to albumin in your blood, extending its half-life from 2 minutes (natural GLP-1) to approximately 7 days - enabling once-weekly dosing.
Developed by Novo Nordisk, semaglutide was first approved as Ozempic (2017) for type 2 diabetes management, then as Wegovy (2021) specifically for chronic weight management at a higher dose (2.4 mg). The same molecule powers both - the difference is dosing and indication.
Key facts
- Class: GLP-1 receptor agonist
- Half-life: ~7 days (weekly dosing)
- Bioavailability: ~89% (subcutaneous)
- Peak weight loss: 16.9% at 68 weeks (STEP 1)
- Cardiovascular: 20% MACE risk reduction (SELECT)
- FDA approved: 2017 (T2D), 2021 (obesity)
- Administration: Weekly subcutaneous injection
- Titration: 0.25 mg → 2.4 mg over 16-20 weeks
How semaglutide works in your body
Semaglutide acts on multiple systems simultaneously. It's not just appetite suppression - it changes the hormonal environment that drives overeating, slows digestion, and improves metabolic signaling.
Appetite regulation
Binds GLP-1 receptors in the hypothalamus, reducing hunger signals and the "food noise" that drives cravings. Patients report thinking about food 60-80% less.
Gastric slowing
Delays gastric emptying by 30-40%, meaning food stays in your stomach longer. You feel full faster, eat smaller portions naturally, and stay satisfied between meals.
Insulin optimization
Enhances glucose-dependent insulin secretion from pancreatic beta cells. Only stimulates insulin when blood sugar is elevated - no hypoglycemia risk in non-diabetics.
Cardiovascular protection
Reduces arterial inflammation, improves endothelial function, and lowers C-reactive protein. The SELECT trial demonstrated a 20% reduction in major adverse cardiovascular events.
The STEP trial program
The Semaglutide Treatment Effect in People with obesity (STEP) program is the largest clinical trial series ever conducted for a weight-loss medication. Here are the key results from each trial.
STEP 1
1,961 adults with BMI ≥30 (or ≥27 with comorbidity). Semaglutide 2.4 mg vs placebo, both with lifestyle intervention, over 68 weeks.
STEP 2
1,210 adults with type 2 diabetes and BMI ≥27. Semaglutide 2.4 mg vs 1.0 mg vs placebo, 68 weeks.
STEP 3
611 adults with obesity, no diabetes. Semaglutide 2.4 mg + intensive behavioral therapy (30 counseling sessions) vs placebo + IBT, 68 weeks.
STEP 4
902 adults. All received semaglutide 2.4 mg for 20 weeks, then randomized to continue semaglutide vs switch to placebo for 48 more weeks.
STEP 5
304 adults with obesity, no diabetes. Semaglutide 2.4 mg vs placebo with lifestyle intervention over 104 weeks (2 years).
SELECT
17,604 adults with overweight/obesity and established cardiovascular disease. Semaglutide 2.4 mg vs placebo. Median follow-up: 39.8 months.
Side effects & tolerability
Most side effects are gastrointestinal, dose-dependent, and resolve during the titration period. Slow titration (starting low, increasing gradually) significantly reduces their severity.
Side effect rates from STEP 1 (semaglutide 2.4 mg vs placebo)
GI side effects are typically mild-to-moderate, most common in the first 4-8 weeks during titration, and resolve as the body adjusts. Only 7% of participants discontinued treatment due to adverse events (vs 3.1% placebo).
Managing common side effects
- Nausea: Eat smaller, more frequent meals. Avoid fatty, fried, or spicy foods. Ginger tea or ginger supplements can help. Symptoms usually diminish after 2-4 weeks at each dose level.
- Diarrhea/Constipation: Stay well hydrated (aim for 64+ oz of water daily). Increase fiber gradually. Consider a stool softener if constipation persists beyond 2 weeks.
- Fatigue: Ensure adequate protein intake (0.7-1 g per pound of body weight). Low protein during rapid weight loss can cause muscle loss and fatigue. Your care team monitors this.
- Injection site reactions: Rotate sites consistently. Let the medication warm to room temperature before injecting. Apply ice before and gentle pressure after.
Weight loss quality: fat vs. muscle
A common concern with rapid weight loss is lean muscle loss. The clinical data on semaglutide's body composition effects is important to understand.
- STEP 1 DEXA substudy: Approximately 40% of weight lost was lean mass, 60% was fat mass - consistent with caloric restriction generally
- Protein intake matters: Patients maintaining adequate protein (0.7-1g/lb) and engaging in resistance training retain significantly more muscle
- Clinical supervision: Regular body composition monitoring allows dose and nutrition adjustments to optimize fat-to-muscle loss ratio
- The net benefit: Even with some lean mass loss, the metabolic improvements (reduced insulin resistance, lower inflammation, cardiovascular protection) dramatically outweigh the risks of remaining obese
How we protect your muscle
At Linux Health, your treatment includes:
- Personalized protein targets based on your body weight
- Resistance training recommendations
- Regular check-ins to monitor energy and strength
- Dose adjustments if weight loss pace exceeds safe range
- Slower titration option for patients with lower BMI
Dosing & pharmacokinetics
Semaglutide's extended half-life enables convenient weekly dosing. Here's how the standard titration works and why it matters.
Weeks 1-4
Body acclimates to GLP-1 stimulation. Mild appetite changes begin. GI side effects are managed at this low dose.
Weeks 5-8
Appetite suppression becomes more noticeable. Most patients begin losing weight consistently at this dose.
Weeks 9-12
Therapeutic effects strengthen. Food noise significantly reduced. Weight loss typically 1-2 lbs/week.
Weeks 13-16
Approaching full therapeutic dose. Most GI side effects have resolved. Steady-state blood levels approaching maximum.
Week 17+
Full therapeutic dose. Maximum appetite regulation and metabolic effects. Maintained for the duration of treatment.
Pharmacokinetic profile
- Time to peak plasma concentration: 1-3 days after injection
- Steady state: Reached after 4-5 weekly doses
- Elimination half-life: ~168 hours (~7 days)
- Protein binding: >99% (bound to albumin)
- Metabolism: Proteolytic degradation (backbone and fatty acid side chain)
- Dose proportionality: Linear across the 0.25-2.4 mg range
Semaglutide FAQ
Related reading
Retatrutide Deep Dive
The triple-agonist peptide: mechanism, trial results, and future potential.
Learn more →Clinical Studies
Trial data, outcomes, and what the research reveals about GLP-1 therapy.
Learn more →Dosing Guide
Titration schedules, dose levels, and what to expect at each stage.
Learn more →The Science
How GLP-1 receptor agonists drive real, lasting weight loss.
Learn more →See if semaglutide therapy is right for you
Free physician-reviewed eligibility screening. Results in under 24 hours.